Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Paolo Calabrò
Institution:
University of Campania "Luigi Vanvitelli"
Observed institutions:
University of Campania "Luigi Vanvitelli",
University of Birmingham
ORCID:
0000-0002-5018-830X
Observed ORCID:
0000-0002-5018-830X
OpenAlex ID:
A5109511896
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
2019
·
Kausik K Ray
, Helen M Colhoun
, et al.
·
The Lancet Diabetes & Endocrinology
·
359
PDF
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial
2019
·
Deepak L Bhatt
, Philippe Gabriel Steg
, et al.
·
The Lancet
·
223
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
2021
·
Gregory G. Schwartz
, Michael Szarek
, et al.
·
Journal of the American College of Cardiology
·
163
PDF
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
2022
·
Emil Hagström
, P. Gabriel Steg
, et al.
·
Circulation
·
129
PDF
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment
2021
·
Gregory G. Schwartz
, Michael Szarek
, et al.
·
Diabetes Care
·
42
PDF
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES
2025
·
P. Gabriel Steg
, Michael Szarek
, et al.
·
Circulation
·
32
PDF
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
2024
·
Shaun G Goodman
, Philippe Gabriel Steg
, et al.
·
European Heart Journal - Cardiovascular Pharmacotherapy
·
29
PDF
Roadmap for cardiovascular education across the European Society of Cardiology: inspiring better knowledge and skills, now and for the future
2018
·
Dipak Kotecha
, Jeroen J Bax
, et al.
·
European Heart Journal
·
23
PDF
Glucagon-Like Peptide-1 Receptor Agonists
2026
·
Arturo Cesaro
, Vincenzo Acerbo
, et al.
·
CRC Press eBooks
Hypertension, smoking and adiposity: old enemies, new priorities in FH
2026
·
Arturo Cesaro
, Paolo Calabrò
, et al.
·
Atherosclerosis
Tirzepatide and semaglutide: different twins?
2026
·
Arturo Cesaro
, Vincenzo Acerbo
, et al.
·
European Heart Journal Supplements
Icosapent etile per la riduzione del rischio cardiovascolare residuo
2025
·
Felice Gragnano
, Paolo Calabrò
·
Cardiologia Ambulatoriale
Show more works
View as search
Works count:
13
Citation count:
1,023
H-index:
9
I10-index:
9
Year
Topic
Type